CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival
Phase of Trial: Phase I
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Belimumab (Primary) ; Alemtuzumab; Mycophenolic acid; Steroids; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CAMPBEL
- 15 Apr 2019 Planned initiation date changed from 15 Mar 2019 to 17 Apr 2019.
- 18 Mar 2019 Planned initiation date (estimated date of first participant enrollement) changed from 15 Mar 2019 to 1 Apr 2019.
- 08 Mar 2019 Planned initiation date (estimated date of first participant enrollement) changed from 5 Mar 2019 to 15 Mar 2019.